FIELD: chemistry.
SUBSTANCE: invention refers to new indazole derivants with the formula (1.0) or to their pharmaceutically acceptable salts and isomerides that act as inactivators in relation to ERK2. In formula (1.0): 
meanings of the chemical groups Q, R1, R2 are given in the invention formula. The invention also refers to the pharmaceutical composition containing the mentioned compounds and to application of the compounds with the formula (1.0) for production of crude drugs used in malignant growth treatment.
EFFECT: application of the compounds for production of crude drugs used in malignant growth treatment.
65 cl, 611 ex, 27 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SUBSTITUTED 8-HETEROARYLXANTINES AND BASED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2357969C2 |
| COMBINATION OF INHIBITORS OF FBP-ASE AND SENSITIZING AGENTS OF INSULIN FOR DIABETES MELLITUS TREATMENT | 1999 |
|
RU2227749C2 |
| ASPARTATE PROTEASE INHIBITORS | 2006 |
|
RU2424231C2 |
| PREPARING STERIC HINDERED AMINE ETHERS | 1999 |
|
RU2224758C2 |
| NEW PHOSPHORUS-CONTAINING THYMOMIMETIC DRUGS | 2004 |
|
RU2422450C2 |
| SUBSTITUTED BICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF INHIBITION | 1998 |
|
RU2204557C2 |
| THERAPEUTICALLY ACTIVE TRIAZOLES AND USE THEREOF | 2007 |
|
RU2469042C2 |
| METHODS AND PRODUCTS FOR HEALING TISSUE WOUNDS | 2012 |
|
RU2652308C2 |
| DEUTERATED BENZYL BENZENE DERIVATES AND METHODS FOR USE | 2009 |
|
RU2509773C2 |
| CONDENSED HETEROCYCLIC COMPOUND | 2009 |
|
RU2480473C2 |
